Summarized by Masters of Longevity from Longevity Technology.
A South Korean RNA-editing company has taken lab space inside a major pharma's San Diego innovation hub to accelerate its US clinical and partnership efforts.
Key Takeaways
- Rznomics joined Lilly Gateway Labs in San Diego to gain wet-lab access and proximity to Lilly scientists.
- Rznomics previously signed a collaboration and licensing deal with Eli Lilly on an RNA-editing therapeutic.
- Rznomics develops trans-splicing ribozymes and is advancing oncology and rare disease candidates toward clinical work.
